<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39103829</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>06</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2334</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>05</Day></PubDate></JournalIssue><Title>BMC infectious diseases</Title><ISOAbbreviation>BMC Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Nirmatrelvir/ritonavir treatment and the risk of post-COVID condition over 180 days in Malaysia.</ArticleTitle><Pagination><StartPage>780</StartPage><MedlinePgn>780</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">780</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12879-024-09679-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The effect of nirmatrelvir/ritonavir on preventing post-COVID condition (PCC) in the BA4, BA5, and XBB Omicron predominant periods is not well understood. The purpose of this study was to assess how nirmatrelvir/ritonavir treatment affected both PCC and health-related quality of life.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This retrospective cohort study enrolled 2,524 adults aged 18 years and older who were eligible for nirmatrelvir/ritonavir between July 14 to November 14, 2022. All outcomes were observed from the patient's first visit to the primary health clinic, 1 week, 1 month, 3 months, and 6 months after testing positive for COVID-19. The primary outcome was the presence of PCC. Secondary outcomes included the effects on health-related quality of life, such as walking, bathing and dressing, activities, cause adverse emotions or signs that prevent individuals from leading normal lives over a 180-day observation period.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were no significant differences observed between the nirmatrelvir/ritonavir and those not administered (control group) in terms of PCC symptoms at 3 months (OR 0.71 95% CI 0.31, 1.64) and 6 months (OR 1.30 95% CI 0.76, 2.21). At 3 months, the use of nirmatrelvir/ritonavir was associated with a 26% reduction in symptoms causing negative emotions (OR 0.74 95% CI 0.60, 0.92) and an increased likelihood of symptoms limiting walking (OR 1.58 95% CI 1.10, 2.27). However, there were no significant differences between the nirmatrelvir/ritonavir and the control group in terms of the impact of PCC on health-related quality of life at 6 months.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study indicates that the administration of nirmatrelvir/ritonavir does not significantly reduce PCC after 3 months and 6 months in a population with high vaccination coverage.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Low</LastName><ForeName>Ee Vien</ForeName><Initials>EV</Initials><AffiliationInfo><Affiliation>Institute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, No.1 Jalan Setia Murni U13/52, Seksyen U13, Shah Alam, Selangor, 40170, Malaysia. evienlow@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Health Systems Research, National Institutes of Health, Ministry of Health Malaysia, No.1 Jalan Setia Murni U13/52, Seksyen U13, Shah Alam, Selangor, 40170, Malaysia. evienlow@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pathmanathan</LastName><ForeName>Mohan Dass</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Institute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, No.1 Jalan Setia Murni U13/52, Seksyen U13, Shah Alam, Selangor, 40170, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ten</LastName><ForeName>Yi Yang</ForeName><Initials>YY</Initials><AffiliationInfo><Affiliation>Institute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, No.1 Jalan Setia Murni U13/52, Seksyen U13, Shah Alam, Selangor, 40170, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chidambaram</LastName><ForeName>Suresh Kumar</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department of Medicine, Sungai Buloh Hospital, Sungai Buloh, Selangor, 47000, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Wee Ric</ForeName><Initials>WR</Initials><AffiliationInfo><Affiliation>Digital Health Division, Ministry of Health Malaysia, Block F1, Complex F, 62000, Putrajaya, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Wei Jia</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Digital Health Division, Ministry of Health Malaysia, Block F1, Complex F, 62000, Putrajaya, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teh</LastName><ForeName>Zhi Wei</ForeName><Initials>ZW</Initials><AffiliationInfo><Affiliation>Digital Health Division, Ministry of Health Malaysia, Block F1, Complex F, 62000, Putrajaya, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Appannan</LastName><ForeName>Maheshwara Rao</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Digital Health Division, Ministry of Health Malaysia, Block F1, Complex F, 62000, Putrajaya, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ismail</LastName><ForeName>Mastura</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Family Health Development Division, Ministry of Health Malaysia, Block E10, Complex E, Putrajaya, 62590, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Samad</LastName><ForeName>Azah Abdul</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Section 7 Health Clinic, No.2 Persiaran Kayangan, Seksyen 7, Shah Alam, Selangor, 40000, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peariasamy</LastName><ForeName>Kalaiarasu M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Institute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, No.1 Jalan Setia Murni U13/52, Seksyen U13, Shah Alam, Selangor, 40170, Malaysia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Taylor's University, No. 1 Jalan Taylor's, Subang Jaya, Selangor, 47500, Malaysia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NIH/800-3/2/2 Jilid 13 (182)</GrantID><Agency>Ministry of Health Malaysia Research Grant</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Infect Dis</MedlineTA><NlmUniqueID>100968551</NlmUniqueID><ISSNLinking>1471-2334</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="Y">Ritonavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008296" MajorTopicYN="N" Type="Geographic">Malaysia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Malaysia</Keyword><Keyword MajorTopicYN="N">Nirmatrelvir/ritonavir</Keyword><Keyword MajorTopicYN="N">post-COVID condition</Keyword></KeywordList><CoiStatement>The authors declare no competing interests. The authors declare that they have no conflict of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>6</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>5</Day><Hour>23</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39103829</ArticleId><ArticleId IdType="pmc">PMC11299408</ArticleId><ArticleId IdType="doi">10.1186/s12879-024-09679-1</ArticleId><ArticleId IdType="pii">10.1186/s12879-024-09679-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ministry of Health Malaysia. COVID-19: What is latest situation in Malaysia? 2024 https://data.moh.gov.my/dashboard/covid-19. Accessed 15 Dec 2023.</Citation></Reference><Reference><Citation>Mohammed I, Nauman A, Paul P, Ganesan S, Chen KH, Jalil SMS, et al. The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review. Hum Vaccin Immunother. 2022;18(1):2027160. 10.1080/21645515.2022.2027160</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2022.2027160</ArticleId><ArticleId IdType="pmc">PMC8862168</ArticleId><ArticleId IdType="pubmed">35113777</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. Benefits of Getting https://www.cdc.gov/coronavirus/2019-ncov/vaccines/vaccine-benefits.html. Accessed 15 Dec 2023.</Citation></Reference><Reference><Citation>Anand R. PM Muhyiddin receives first Covid-19 vaccine as Malaysia kicks off mass innoculation campaign. Straits Time. 2021.</Citation></Reference><Reference><Citation>Ministry of Health Malaysia. COVIDNOW: Vaccination Progress 2023. https://covidnow.moh.gov.my/vaccinations/?refresh=1720781109523. Accessed 1 January 2024.</Citation></Reference><Reference><Citation>Sim BLH, Chidambaram SK, Wong XC, Pathmanathan MD, Peariasamy KM, Hor CP, et al. Clinical characteristics and risk factors for severe COVID-19 infections in Malaysia: a nationwide observational study. Lancet Reg Health West Pac. 2020;4:100055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7837062</ArticleId><ArticleId IdType="pubmed">33521741</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. Underlying Medical Conditions 2023. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html. Accessed 15 Dec 2023.</Citation></Reference><Reference><Citation>Dryden M, Mudara C, Vika C, Blumberg L, Mayet N, Cohen C, et al. Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in South Africa: a prospective cohort study. Lancet Glob Health. 2022;10(9):e1247&#x2013;56. 10.1016/S2214-109X(22)00286-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(22)00286-8</ArticleId><ArticleId IdType="pmc">PMC9363040</ArticleId><ArticleId IdType="pubmed">35961348</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention, Long COVID. 2023. https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html. Accessed 15 Dec 2023.</Citation></Reference><Reference><Citation>O&#x2019;Mahoney LL, Routen A, Gillies C, Ekezie W, Welford A, Zhang A, et al. The prevalence and long-term health effects of long covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. EClinicalMedicine. 2023;55:101762. 10.1016/j.eclinm.2022.101762</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101762</ArticleId><ArticleId IdType="pmc">PMC9714474</ArticleId><ArticleId IdType="pubmed">36474804</ArticleId></ArticleIdList></Reference><Reference><Citation>National Istitue for Health and Care Excellence (NICE). Royal College of General Practitioner (RCGP); Scottish intercollegiate Guidelines Network (SIGN); COVID-19 rapid guidelines: managing the long term effects of COVID-19. 2022. Accessed 15 Dec 2023.</Citation></Reference><Reference><Citation>Government of Canada. Post COVID-19 condition (long COVID) 2023 [updated March 9. 2023. https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/symptoms/post-covid-19-condition.html. Accessed 15 Dec 2023.</Citation></Reference><Reference><Citation>Department of Health and Aged Care, Long COVID. 2023 https://www.health.gov.au/topics/covid-19/long-covid. Accessed 15 Dec 2023.</Citation></Reference><Reference><Citation>Woodrow M, Carey C, Ziauddeen N, Thomas R, Akrami A, Lutje V, et al. Systematic review of the prevalence of long COVID. Open Forum Infect Dis. 2023;10(7):ofad233. 10.1093/ofid/ofad233</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofad233</ArticleId><ArticleId IdType="pmc">PMC10316694</ArticleId><ArticleId IdType="pubmed">37404951</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA. FDA Approves First Oral Antiviral for Treatment of COVID-19 in Adults. 2023 https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-antiviral-treatment-covid-19-adults. Accessed 15 Nov 2023.</Citation></Reference><Reference><Citation>Aggarwal NR, Molina KC, Beaty LE, Bennett TD, Carlson NE, Mayer DA et al. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. The Lancet Infectious Diseases.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10014040</ArticleId><ArticleId IdType="pubmed">36780912</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbel R, Wolff Sagy Y, Hoshen M, Battat E, Lavie G, Sergienko R, et al. Nirmatrelvir use and severe Covid-19 outcomes during the Omicron Surge. N Engl J Med. 2022;387(9):790&#x2013;8. 10.1056/NEJMoa2204919</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2204919</ArticleId><ArticleId IdType="pmc">PMC9454652</ArticleId><ArticleId IdType="pubmed">36001529</ArticleId></ArticleIdList></Reference><Reference><Citation>Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, et al. Effectiveness of Paxlovid in reducing severe coronavirus Disease 2019 and mortality in high-risk patients. Clin Infect Dis. 2022;76(3):e342&#x2013;9.10.1093/cid/ciac443</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac443</ArticleId><ArticleId IdType="pmc">PMC9214014</ArticleId><ArticleId IdType="pubmed">35653428</ArticleId></ArticleIdList></Reference><Reference><Citation>Wai AK-C, Chan CY, Cheung AW-L, Wang K, Chan SC-L, Lee TT-L et al. Association of Molnupiravir and Nirmatrelvir-Ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19. Lancet Reg Health &#x2013; Western Pac. 2023;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9532222</ArticleId><ArticleId IdType="pubmed">36212676</ArticleId></ArticleIdList></Reference><Reference><Citation>Marzi M, Vakil MK, Bahmanyar M, Zarenezhad E, Paxlovid. Mechanism of action, synthesis, and in Silico Study. Biomed Res Int. 2022;2022:7341493.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9283023</ArticleId><ArticleId IdType="pubmed">35845944</ArticleId></ArticleIdList></Reference><Reference><Citation>Congdon S, Narrowe Z, Yone N, Gunn J, Deng Y, Nori P, et al. Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study. Sci Rep. 2023;13(1):19688. 10.1038/s41598-023-46912-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-46912-4</ArticleId><ArticleId IdType="pmc">PMC10640584</ArticleId><ArticleId IdType="pubmed">37951998</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Choi T, Al-Aly Z. Association of Treatment with Nirmatrelvir and the risk of Post&#x2013;COVID-19 Condition. JAMA Internal Medicine; 2023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10037200</ArticleId><ArticleId IdType="pubmed">36951829</ArticleId></ArticleIdList></Reference><Reference><Citation>National Pharmaceutical Regulatory Agency. SENARAI PRODUK &#x2013; PRODUK YANG TELAH DILULUSKAN OLEH PIHAK BERKUASA KAWALAN DADAH (PBKD.) DALAM MESYUARAT PBKD KALI KE &#x2013; 370. 2022.</Citation></Reference><Reference><Citation>Lewnard JA, McLaughlin JM, Malden D, Hong V, Puzniak L, Ackerson BK, et al. Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system. The Lancet Infectious Diseases; 2023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10081864</ArticleId><ArticleId IdType="pubmed">36933565</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai CC, Wang YH, Chen KH, Chen CH, Wang CY. The clinical efficacy and safety of anti-viral agents for non-hospitalized patients with COVID-19: a systematic review and network Meta-analysis of Randomized controlled trials. Viruses. 2022;14(8).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9415971</ArticleId><ArticleId IdType="pubmed">36016328</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong CKH, Lau KTK, Leung GM. Real-world effectiveness of nirmatrelvir/ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants. Lancet Infect Dis. 2023;23(6):639&#x2013;40. 10.1016/S1473-3099(23)00056-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00056-7</ArticleId><ArticleId IdType="pmc">PMC9917404</ArticleId><ArticleId IdType="pubmed">36780911</ArticleId></ArticleIdList></Reference><Reference><Citation>Low EV, Pathmanathan MD, Chidambaram SK, Kim WR, Lee WJ, Teh ZW, et al. Real-world nirmatrelvir-ritonavir outpatient treatment in reducing hospitalization for high-risk patients with COVID-19 during Omicron BA.4, BA.5 and XBB subvariants dominance in Malaysia: a retrospective cohort study. Int J Infect Dis. 2023;135:77&#x2013;83. 10.1016/j.ijid.2023.08.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2023.08.003</ArticleId><ArticleId IdType="pubmed">37567557</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajema KL, Berry K, Streja E, Rajeevan N, Li Y, Mutalik P, et al. Effectiveness of COVID-19 Treatment with Nirmatrelvir-Ritonavir or Molnupiravir among U.S. veterans: Target Trial Emulation Studies with one-Month and Six-Month outcomes. Ann Intern Med. 2023;176(6):807&#x2013;16. 10.7326/M22-3565</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M22-3565</ArticleId><ArticleId IdType="pmc">PMC10243488</ArticleId><ArticleId IdType="pubmed">37276589</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, Pocock SJ, G&#xf8;tzsche PC, Vandenbroucke JP. The strengthening the reporting of Observational studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453&#x2013;7. 10.1016/S0140-6736(07)61602-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(07)61602-X</ArticleId><ArticleId IdType="pubmed">18064739</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Health Malaysia. Clinical Management of Confirmed COVID-19 Case in Adult and Paediatric 2022. https://covid-19.moh.gov.my/garis-panduan/garis-panduan-kkm/ANNEX-2E-CLINICAL-MANAGEMENT-OF-CONFIRMED-COVID-19-31052022.pdf. Accessed 15 Nov 2023.</Citation></Reference><Reference><Citation>Tok PSK, Kang KY, Ng SW, Ab Rahman N, Syahmi MA, Pathmanathan MD, et al. Post COVID-19 condition among adults in Malaysia following the Omicron wave: a prospective cohort study. PLoS ONE. 2024;19(1):e0296488. 10.1371/journal.pone.0296488</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0296488</ArticleId><ArticleId IdType="pmc">PMC10769055</ArticleId><ArticleId IdType="pubmed">38181017</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Post COVID-19 condition (COVID-19) 2022 https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition. Accessed 15 November 2023.</Citation></Reference><Reference><Citation>Magnusson K, Kristoffersen DT, Dell&#x2019;Isola A, Kiadaliri A, Turkiewicz A, Runhaar J, et al. Post-covid medical complaints following infection with SARS-CoV-2 omicron vs Delta variants. Nat Commun. 2022;13(1):7363. 10.1038/s41467-022-35240-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-35240-2</ArticleId><ArticleId IdType="pmc">PMC9709355</ArticleId><ArticleId IdType="pubmed">36450749</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedberg P, Naucl&#xe9;r P. Post-COVID-19 Condition after SARS-CoV-2 infections during the Omicron Surge vs the Delta, Alpha, and wild type periods in Stockholm, Sweden. J Infect Dis. 2024;229(1):133&#x2013;6. 10.1093/infdis/jiad382</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad382</ArticleId><ArticleId IdType="pmc">PMC10786247</ArticleId><ArticleId IdType="pubmed">37665981</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders C, Sperling S, Bendstrup E. A new paradigm is needed to explain long COVID. Lancet Respiratory Med. 2023;11(2):e12&#x2013;3.10.1016/S2213-2600(22)00501-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00501-X</ArticleId><ArticleId IdType="pubmed">36620963</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu TH, Wu JY, Huang PY, Tsai YW, Lai CC. The effect of nirmatrelvir-ritonavir on the long-term risk of neuropsychiatric sequelae following COVID-19. J Med Virol. 2023;95(7):e28951. 10.1002/jmv.28951</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28951</ArticleId><ArticleId IdType="pubmed">37436873</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>